These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 23577184)

  • 1. Clinical profile of PiB-positive corticobasal syndrome.
    Burrell JR; Hornberger M; Villemagne VL; Rowe CC; Hodges JR
    PLoS One; 2013; 8(4):e61025. PubMed ID: 23577184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDG-PET Patterns Predict Amyloid Deposition and Clinical Profile in Corticobasal Syndrome.
    Parmera JB; Coutinho AM; Aranha MR; Studart-Neto A; de Godoi Carneiro C; de Almeida IJ; Fontoura Solla DJ; Ono CR; Barbosa ER; Nitrini R; Buchpiguel CA; Brucki SMD
    Mov Disord; 2021 Mar; 36(3):651-661. PubMed ID: 33206389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [
    Ali F; Whitwell JL; Martin PR; Senjem ML; Knopman DS; Jack CR; Lowe VJ; Petersen RC; Boeve BF; Josephs KA
    J Neurol; 2018 May; 265(5):1079-1088. PubMed ID: 29497818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic and Structural Signatures of Speech and Language Impairment in Corticobasal Syndrome: A Multimodal PET/MRI Study.
    Parmera JB; de Almeida IJ; de Oliveira MCB; Silagi ML; de Godoi Carneiro C; Studart-Neto A; Ono CR; Reis Barbosa E; Nitrini R; Buchpiguel CA; Brucki SMD; Coutinho AM
    Front Neurol; 2021; 12():702052. PubMed ID: 34526958
    [No Abstract]   [Full Text] [Related]  

  • 5. Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients.
    Lehmann M; Ghosh PM; Madison C; Karydas A; Coppola G; O'Neil JP; Huang Y; Miller BL; Jagust WJ; Rabinovici GD
    J Neurol Neurosurg Psychiatry; 2014 Mar; 85(3):266-73. PubMed ID: 23965289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.
    Jack CR; Lowe VJ; Weigand SD; Wiste HJ; Senjem ML; Knopman DS; Shiung MM; Gunter JL; Boeve BF; Kemp BJ; Weiner M; Petersen RC;
    Brain; 2009 May; 132(Pt 5):1355-65. PubMed ID: 19339253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.
    Jack CR; Lowe VJ; Senjem ML; Weigand SD; Kemp BJ; Shiung MM; Knopman DS; Boeve BF; Klunk WE; Mathis CA; Petersen RC
    Brain; 2008 Mar; 131(Pt 3):665-80. PubMed ID: 18263627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.
    Förster S; Yousefi BH; Wester HJ; Klupp E; Rominger A; Förstl H; Kurz A; Grimmer T; Drzezga A
    Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1927-36. PubMed ID: 22926714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography.
    Sha SJ; Ghosh PM; Lee SE; Corbetta-Rastelli C; Jagust WJ; Kornak J; Rankin KP; Grinberg LT; Vinters HV; Mendez MF; Dickson DW; Seeley WW; Gorno-Tempini M; Kramer J; Miller BL; Boxer AL; Rabinovici GD
    Alzheimers Res Ther; 2015; 7(1):8. PubMed ID: 25733984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measuring disease progression in corticobasal syndrome.
    Huang N; Hornberger M; Hodges JR; Burrell JR
    J Neurol; 2014 Aug; 261(8):1598-605. PubMed ID: 24893591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET.
    Edison P; Carter SF; Rinne JO; Gelosa G; Herholz K; Nordberg A; Brooks DJ; Hinz R
    Neuroimage; 2013 Apr; 70():423-33. PubMed ID: 23261639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
    Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF Alzheimer's disease-like pattern in corticobasal syndrome: evidence for a distinct disorder.
    Borroni B; Premi E; Agosti C; Alberici A; Cerini C; Archetti S; Lanari A; Paghera B; Lucchini S; Caimi L; Padovani A
    J Neurol Neurosurg Psychiatry; 2011 Aug; 82(8):834-8. PubMed ID: 21345847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo demonstration of amyloid burden in posterior cortical atrophy: a case series with PET and CSF findings.
    Formaglio M; Costes N; Seguin J; Tholance Y; Le Bars D; Roullet-Solignac I; Mercier B; Krolak-Salmon P; Vighetto A
    J Neurol; 2011 Oct; 258(10):1841-51. PubMed ID: 21479849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impact of (11)C-Pittsburgh compound-B positron emission tomography carried out in addition to magnetic resonance imaging and single-photon emission computed tomography on the diagnosis of Alzheimer's disease in patients with dementia and mild cognitive impairment.
    Omachi Y; Ito K; Arima K; Matsuda H; Nakata Y; Sakata M; Sato N; Nakagome K; Motohashi N
    Psychiatry Clin Neurosci; 2015 Dec; 69(12):741-51. PubMed ID: 26085054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hippocampal and cortical atrophy in amyloid-negative mild cognitive impairments: comparison with amyloid-positive mild cognitive impairment.
    Ye BS; Seo SW; Kim CH; Jeon S; Kim GH; Noh Y; Cho H; Yoon CW; Kim HJ; Jang EY; Lee J; Kim JH; Chin J; Lee JM; Kim JH; Seong JK; Kim CH; Choe YS; Lee KH; Na DL
    Neurobiol Aging; 2014 Feb; 35(2):291-300. PubMed ID: 24080178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of 11C-Pittsburgh compound-B positron emission tomography in addition to magnetic resonance imaging and single-photon emission computed tomography on diagnosis of mild cognitive impairment to Alzheimer's disease.
    Kitajima K; Abe K; Takeda M; Yoshikawa H; Ohigashi M; Osugi K; Koyama H; Yamakado K
    Medicine (Baltimore); 2021 Jan; 100(3):e23969. PubMed ID: 33545981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B.
    Ng SY; Villemagne VL; Masters CL; Rowe CC
    Arch Neurol; 2007 Aug; 64(8):1140-4. PubMed ID: 17698704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical features of Pittsburgh compound-B-negative dementia.
    Takeuchi J; Shimada H; Ataka S; Kawabe J; Mori H; Mizuno K; Wada Y; Shiomi S; Watanabe Y; Miki T
    Dement Geriatr Cogn Disord; 2012; 34(2):112-20. PubMed ID: 22947919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
    Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
    Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.